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Modulation of Bax by PKC: An approach to eliminate cancer cells 
 
Abstract 
Apoptosis is a type of cell death, known as a highly regulated program of 
cellular suicide; however this process is often deregulated in tumor cells. A mechanism 
used by tumor cells to evade apoptosis is the alteration of the different members of the 
Bcl-2 family. These proteins control a key step in the intrinsic apoptotic pathway: 
permeabilization of the outer mitochondrial membrane and release of several apoptotic 
factors. The pro-apoptotic members Bax and Bak are essential for this 
permeabilization, since deletion of either protein compromises the intrinsic apoptotic 
pathway. These proteins may be regulated by members of the Bcl-2 but also by other 
proteins, such as the protein kinase C (PKC) family. 
The PKC family consists of kinases that regulate a variety of cellular functions. 
Of these, PKCepsilon (PKC) is involved in carcinogenesis and has been considered 
an oncogene. It has been shown that this protein increases the expression of anti-
apoptotic members of the Bcl-2 family and inhibits the pro-apoptotic members such as 
Bax. The interaction between Bax and PKC in mammalian cells prevents Bax 
translocation to the outer mitochondrial membrane, leading to a decrease in its 
activation. Identifying residues required for this interaction is therefore crucial to design 
a strategy to inhibit it. 
In this work, we aimed to identify residues required for the Bax/PKC  
interaction. For this purpose, different domains of PKC cloned in frame with the FLAG 
epitope in a yeast inducible expression vector were co-expressed with Bax in 
Saccharomyces cerevisiae, in order to evaluate their interaction with Bax.  An 
alternative approach using yeast-two-hybrid was also pursued to verify the interaction 
between these two proteins. Our ultimate goal is to develop specific modulators to 
target the PKC/Bax interaction that could open the door to new clinical opportunities 
for cancer treatment. 
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Modulation of Bax by PKC: An approach to eliminate cancer cells 
 
Resumo 
A apoptose é um tipo de morte celular, mais conhecida como um programa de 
suicídio celular altamente regulado. No entanto, em células tumorais este processo 
está frequentemente desregulado. Um mecanismo usado pelas células tumorais para 
escapar à apoptose é a alteração dos níveis de expressão dos diferentes membros da 
família Bcl-2. Estas proteínas controlam um passo essencial da via apoptótica 
intrínseca, a permeabilização da membrana mitocondrial externa e a libertação de 
vários fatores apoptóticos. Os membros pró-apoptóticos Bax e Bak são essenciais 
para esta permeabilização, pois a deleção de ambas as proteínas compromete a via 
apoptótica intrínseca. Estas proteínas podem ser reguladas pelos membros da família 
Bcl-2 mas também por outras proteínas, como as proteínas da família da cinase C 
PKC). 
A família PKC é uma família de cinases que regulam uma grande variedade de 
funções celulares. Em particular, a PKCepsilon (PKC) está envolvida na 
carcinogénese e tem sido considerada um oncogene. Tem sido demonstrado que esta 
proteína aumenta a expressão dos membros anti-apoptóticos da família Bcl-2 e inibe 
os membros pró-apoptóticos, como a proteína Bax. A interação entre a PKC e a 
proteína Bax em células de mamíferos leva a que haja uma diminuição da ativação da 
Bax e da sua translocação para a membrana mitocondrial externa, impedindo que a 
Bax desempenhe a sua função na apoptose. Assim, a identificação dos resíduos 
responsáveis para esta interação torna-se extremamente importante para que se 
consiga encontrar um método de a inibir. 
Neste trabalho pretendeu-se identificar os resíduos necessários para essa 
interação. Para este efeito, os diferentes domínios de PKC clonados como fusões 
com o epítopo FLAG num vector de expressão indutível em levedura, foram co-
expressos com Bax em Saccharomyces cerevisiae a fim de avaliar a sua interação 
com Bax. Uma abordagem alternativa usando a técnica de Yeast-two-hybrid também 
foi efetuada para verificar a interação entre PKC e Bax. O objetivo final seria o 
desenvolvimento de moduladores específicos para inibir a interação PKC/ Bax de 
modo a abrir a porta para novas oportunidades clínicas no tratamento de cancro.  
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The work developed in the scope of this thesis includes the study of Bax 
modulation by PKC initially planned and presented in chapter 1, and a 
study of Bax modulation by Nt-acetyltransferase B reported in chapter 2.  
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Bax modulation by PKC  
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1. General Introduction 
 
1.1. Cell death 
The historical development of the concept of cell death originated in 1880 when 
Weigert and Cohnheim described the appearance of necrotic cell death in tissue by 
microscopy. In 1885, Flemming described the process chromatolysis (first name of 
apoptosis) (Majno & Joris, 1995), in which the nucleus of mammalian ovarian follicles 
broke and disappeared by a process of cell death (Kam & Ferch, 2000). Since the mid 
19th century, many observations indicate that cell death plays an important role in the 
physiological processes of multicellular organisms, particularly during embryogenesis 
and metamorphosis. The term programmed cell death (PCD) was introduced in 1964 
(Majno & Joris, 1995), suggesting that cell death during development is not accidental 
in nature, but follows a controlled sequence of steps leading to cellular destruction. In 
turn, the term apoptosis, a form of PCD, was first used in articles by Kerr, Wyllie and 
Currie in 1972 to describe a morphologically distinct form of cell death, although some 
features of apoptosis were explicitly described many years before (Elmore, 2007). 
Apoptosis was later recognized and accepted as an important characteristic mode of 
PCD with distinct morphologic characteristics from those found in necrosis. Nowadays, 
the Nomenclature Committee on Cell Death proposes the term regulated cell death 
(RCD) as a broader term for a genetically controlled death, in contrast to accidental cell 
death, and reserves the term programmed cell death for RCD instances that occur as 
part of a developmental program or to preserve physiologic adult tissue homeostasis. 
The three major pathways of RCD are: apoptotic, necrotic and autophagic (Galluzzi et 
al., 2015). 
 
 
1.2. Apoptosis 
The term apoptosis is derived from the Greek meaning “dropping off,” and refers to 
the falling of leaves from trees in autumn. Since apoptosis was described by Kerr et al 
in the 70´s, it is used in contrast to necrosis, to describe the situation in which a cell 
actively pursues a course toward death upon receiving certain stimuli (Wong, 2011). 
This process normally occurs during differentiation, aging, and as a homeostatic 
mechanism to maintain populations of cells in the tissue (Elmore, 2007). 
Apoptosis and necrosis are the two modes of cell death whose molecular 
mechanisms have been studied in most detail. Although originally thought to be 
mutually exclusive, recent discoveries show cellular contexts that require a balanced 
interaction between these two modes of cell death (Nikoletopoulou et al., 2013). 
Intoduction 
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Autophagy is predominantly a cytoprotective process that begins with formation of 
autophagosomes, double membrane-bound structures surrounding cytoplasmic 
macromolecules and organelles destined for recycling. Autophagy has been associated 
with necrosis and apoptosis and plays a crucial role in cell survival and homeostasis. 
However, it also plays a pro-death function since excessive stress results in autophagic 
cell death (Nikoletopoulou et al., 2013) (Ouyang et al., 2012). 
During the early process of apoptosis, cell shrinkage and pyknosis are the most 
visible morphological characteristics. With cell shrinkage, the cells are smaller in size, 
the cytoplasm is dense and the organelles are more tightly packed. Biochemical 
changes include chromosomal DNA cleavage into internucleosomal fragments, 
phosphatidylserine externalization and cleavage of a number of intracellular substrates 
by specific proteolysis (Ouyang et al., 2012) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1. Apoptotic pathways 
Similarly to other pathways, apoptosis can be initiated by activation of various 
internal and external factors, such as activation of death receptors at the plasma 
membrane or through mitochondrial membrane permeabilization. 
The two most common apoptotic pathways are usually described as intrinsic 
(mitochondrial) and extrinsic (death receptor), which eventually can lead to a common 
Figure 1.  Molecular and morphological events associated with the different types of cell 
death: apoptosis, autophagic cell death and necrosis (Tan et al., 2014). 
Autophagic 
cell death 
Intoduction 
4 
 
path; the third is less well known, and is executed through the endoplasmic reticulum 
(Wong, 2011) (Figure 2). 
 
 
1.2.1.1. Major apoptotic pathways and their regulation 
The extrinsic pathway is one of the best characterized apoptotic signaling pathways 
and is triggered when death ligands bind to a death receptor. Although several death 
receptors have been described, the best characterized are the tumor necrosis factor 
TNF 1 receptor (TNFR1) and Fas (CD95); its ligands are referred to as TNF and Fas 
(FasL), respectively (Wong, 2011). In Fas signaling, FasL binds to Fas, leading to 
receptor trimerization. Adaptor proteins bind to the cytosolic death domains (DD) of Fas 
protein (Fas-associated death domain,FADD) via their DDs. In addition, FADD contains 
a death effector domain (DED), to which the DED of pro-caspase-8 can bind. The 
complex of Fas, FasL, FADD and pro-caspase-8 is called the DISC. The procaspase-8 
molecules are brought into close proximity in the DISC, so that they can transactivate 
one another. Active caspase-8 then can directly cleave caspase-3 or other executioner 
caspases, eventually leading to the apoptotic outcome. Its active form, caspase 3, will 
cleave the inhibitor of caspase-activated deoxyribonuclease, responsible for nuclear 
apoptosis (Lawen, 2003). DISC signaling can be inhibited by c-FLIP, a dominant 
negative caspase-8, which leads to the formation of a signaling-inactive DISC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of death receptor (DR) and mitochondrial pathways for the 
induction of apoptosis (Pope, 2002). 
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The intrinsic apoptotic pathway may be activated in response to stress conditions, 
such as hypoxia, oncogene activation, or DNA damage caused by radiation or 
chemicals (Jia et al., 2012). The apoptotic signal leads to the release of cytochrome c 
(cyt c) from the mitochondrial intermembrane space into the cytosol, where it binds to 
the Apoptotic Protease Activating Factor-1 (Apaf-1). 
The mitochondrial pathway of apoptosis begins with permeabilization of the 
mitochondrial outer membrane (MOMP). The mechanisms through which this occurs 
remain controversial, thought permeabilization is usually characterized as either 
permeability transition pore- (PTP) dependent or independent. The exact molecular 
composition of the PT is still unknown but the main components are the matrix 
protein cyclophilin D, the inner mitochondrial membrane protein adenine nucleotide 
translocator (ANT), and the outer mitochondrial membrane protein voltage dependent 
anion channel (VDAC) (Green & Kroemer, 2004). 
In response to apoptotic stimuli, pro-apoptotic members of the Bcl-2 protein family 
(Bax and Bak) become activated and act on the mitochondria to induce the release of 
cyt c. Other pro-apoptotic proteins are also released by the mitochondria, including 
Smac/Diablo (Second Mitochondrial derived activator of Caspase/Direct IAP-Binding 
protein with a Low pI), the serine protease Omi/HtrA2, endonuclease G (EndoG) and 
apoptosis inducing factor (AIF) (Portt et al., 2011). 
The cytoplasmic release of cyt c will activate caspase 3 by forming a complex 
known as the apoptosome, which is formed by binding of cyt c to the cytoplasmic 
adapter protein Apaf-1, ATP or dATP, which recruits pro-caspase 9 (cysteine 
protease); the heptamer formed by these apoptotic factors activates pro-caspase 3. 
Smac/DIABLO released from the mitochondrial intermembrane space enhances this 
cascade by binding to IAP (inhibitor of apoptosis protein), which subsequently leads to 
disruption of the interaction between IAPs and caspase 3, promoting apoptosis 
(Sukhanova et al., 2012). 
 
 
1.2.2. The Bcl-2 family members 
The Bcl-2 gene was first identified by its involvement in B-cell lymphomas, and 
encodes a protein of 25-26 kDa. The proteins of the Bcl-2 family do not just regulate 
apoptosis, they also have alternate functions in other homeostatic pathways, including 
glucose metabolism, cell cycle checkpoints, DNA damage and regulation of 
mitochondrial morphology (Danial, 2007). 
The Bcl-2 family consists of at least thirty related proteins characterized by the 
presence of up to four conserved domains called BH (Tzifi et al., 2012). Most members 
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of the Bcl-2 family contain a transmembrane domain in their C-terminus, which 
encodes a stretch of hydrophobic amino acids important for targeting to intracellular 
membranes, closely associated with their ability to regulate apoptosis. Subcellular 
localization studies confirmed that proteins of the Bcl-2 family are present in the 
mitochondrial outer membrane (MOM), in the nuclear membrane and in the 
endoplasmic reticulum (Brown, 1997). The BH4 domain of Bcl-2 comprises 26 amino 
acids and the structure shows an amphipathic character after interaction with 
membranes, like antimicrobial peptides (Tzifi et al., 2012). 
The Bcl-2 family of proteins is divided into two different sub-classes based on 
structural and functional characteristics: the anti-apoptotic members such as Bcl-2, Bcl-
xL, Bcl-w and MCL-1 contain all four subtypes of BH domains, and promote cell 
survival by inhibiting the function of pro-apoptotic members. The pro-apoptotic 
members can be separated into two structurally distinct subfamilies: 1) "multidomain" 
proteins Bax and Bak, which share three BH regions and lack the BH4 domain. They 
are structurally similar to the anti-apoptotic proteins; 2) BH3-only proteins, including 
BNIP3, Nix/Bnip3L, Bid, Noxa, Puma, Bim and Bad, share only the BH3 domain and 
are structurally diverse (Figure 3) (Gustafsson & Gottlieb, 2007). 
 
Expression of Bcl-2 or other related anti-apoptotic proteins, including myeloid cell 
leukemia-1 (Mcl-1), Bcl-XL, Bcl-w and Bcl-2-related protein A1 (Bfl-1), block cell death 
in response to many stimuli by preventing the activation and homooligomerization of 
both Bax and Bak. Anti-apoptotic proteins perform their anti-death function by 
sequestering BH3-only proteins or inactivating Bax and Bak. Cells that survive 
continuous, permanent death signaling owing to the presence of Bcl-2 are dependent 
on Bcl-2 for their survival (Figure 4) (Brunelle & Letai, 2009). 
Figure 3. Schematic representation of members of each Bcl-2 sub-family. Bcl-2 homology (BH) 
and the transmembrane domains (TM) are indicated. Image adapted from (Jesenberger & Jentsch, 2002). 
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BH3 proteins with high affinity for binding and activating Bax and Bak are 
designated as “activators,” and those that only bind to antiapoptotic proteins are called 
“sensitizers.” The activators interact and activate Bax and Bak to promote MOMP while 
sensitizer proteins compete for binding with the antiapoptotic proteins releasing the 
activators and promoting MOMP through activation and oligomerization of Bax and Bak 
(Shamas-Din et al., 2013). The antiapoptotic proteins inhibit MOMP by sequestering 
the BH3 activators. 
 
 
 
 
 
Figure 4.  Models of Bcl-2 protein regulation in apoptosis. A: BH3-only proteins bind to and neutralize 
anti-apoptotic Bcl-2 proteins, allowing Bax/Bak to become activated and initiate apoptosis. B: BH3-only 
proteins directly activate pro-apoptotic Bax/Bak protein. C: Anti-apoptotic Bcl-2 proteins sequester BH3-only 
proteins and keep them inactive. Image adapted from (Brunelle & Letai, 2009). 
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1.2.2.1. Bax  
Bax resides mainly in the cytosol and translocates to the mitochondria after 
induction of apoptosis. The mitochondrial form of Bax found in non-apoptotic cells is a 
monomer of 21 kDa weakly associated with the MOM or soluble in the cytosol. After 
induction of apoptosis, the monomer progresses to a complex of high molecular weight 
(96-260 kDa), suggesting that the oligomerization of Bax occurs after insertion in the 
MOM (Cartron et al., 2008) (Er et al., 2006). A small portion of Bax was also found in 
the endoplasmic reticulum, although the function of this subpopulation remains 
undetermined. The Bax protein is composed of nine helices connected by short loops. 
Three of these helices, namely α5, α6 and α9, are probably involved in the interaction 
of Bax with the mitochondrial outer membrane. Indeed, the helices 5 and 6 of the Bax 
hydrophobic hairpin may independently form pores in lipid membranes (Walensky & 
Gavathiotis, 2011). The α9 helix is hydrophobic, and although it has the necessary 
characteristics of a transmembrane helix, experimental data suggest that it is not a 
typical transmembrane anchor of α-helices of the C-terminal of anti-apoptotic proteins 
of the Bcl-2 family  (Renault & Manon, 2011). 
The first nineteen residues of Bax are very mobile and data suggests that removal 
of these residues, leading to initiation of translation at the Met20 residue, results in a 
protein with a strong ability to be inserted into the MOM. Renault and Manon suggest 
that the N-terminal domain of Bax has the ability to lock the protein in a soluble and 
inactive conformation and that its movement is necessary to facilitate mitochondrial 
translocation of Bax; this domain is called "Apoptotic Regulation of Targeting" (ART). 
The ART of Bax contains two proline residues at position 8 and 13, and replacement of 
Pro8 or Pro13 by Gly promotes mitochondrial translocation of Bax in both yeast and 
human cells and in human cells undergoing apoptosis. This suggests that interactions 
between ART residues and residues located in other domains of Bax are central 
regulators of the movements of ART and subsequently the mitochondrial translocation 
of Bax (Renault & Manon, 2011). 
 
Homo-oligomerization of Bax requires its BH3 death-domain (the α2 helix). Deletion 
of Bax segments suggests that its α2–α5 helices alone can oligomerize and that this 
core, together with α9, suffices for MOMP. Recent crosslinking studies suggest that 
homo-oligomerization of Bax starts when the BH3 domain of one monomer is exposed 
and engages the canonical binding groove (mainly α3–α5) of another activated 
monomer, forming “BH3-in-groove” dimers that multimerize by a separate interface 
(Czabotar et al., 2013). 
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1.2.2.2. Bax activation and involvement in MOMP 
Several models of MOMP have been proposed: nonspecific MOM rupture or the 
formation of specific channels in the MOM. 
One of the proposed models involves the rupture of the MOM after swelling of the 
mitochondrial matrix and opening of the PTP. The opening of this channel leads to 
swelling of mitochondria, which causes rupture of the MOM and the massive release of 
cyt c. However, several studies showed that the swelling is not an absolute pre-
requisite for apoptosis in vivo and release of cyt c can occur in the absence of 
mitochondrial depolarization (Er et al., 2006). 
Other studies have examined the ability of Bcl-2 family proteins to render lipid bilayers 
permeable to proteins. Tsujimoto et al reported that Bax interacts with voltage-
dependent anion channel (VDAC), an abundant protein in the MOM; moreover, these 
investigators observed that Bax stimulated the release of cyt c, but not of larger 
proteins, from liposomes reconstituted with VDAC, apparently through a widening of 
the VDAC pore just large enough to allow efflux of cyt c (Kuwana & Newmeyer, 2003). 
Kuwana et al. showed that Bcl-2-family proteins can themselves permeabilize lipid 
bilayers, allowing the release of macromolecules considerably larger than cyt c. This 
group also found that the signature mitochondrial lipid cardiolipin was required not 
merely for the targeting of Bid to mitochondrial membranes, but also for the membrane 
permeabilizing activity of Bax (Kuwana & Newmeyer, 2003). Similarly to VDAC, Bax 
and ANT may also form some kind of protein pore. Additionally, since these two 
proteins play important roles in facilitating the transport of small metabolites and 
nucleotides across the mitochondrial membrane, binding of Bax may also contribute to 
the observed blockage of ATP/ADP exchange and the export of creatine phosphate 
during apoptosis induced by cytokine withdrawal (Wang, 2001). 
Further investigations showed that Bax interacts with a component of the 
translocase of the MOM called TOM22, and that depleting this component from 
isolated mitochondria and whole cells decreases Bax translocation and the ability to 
trigger apoptosis. The interaction between Bax and TOM22 is transient, supporting the 
hypothesis that association of Bax with the TOM complex is the first step in the 
formation of another structure containing oligomeric Bax and possibly other 
mitochondrial targets (Renault & Manon, 2011) (Bellot et al., 2007). 
In other models, Bax is constitutively active and therefore must be inhibited by anti-
apoptotic proteins for the cell to survive. To initiate apoptosis, BH3 proteins displace 
Bax from the anti-apoptotic proteins to promote Bax-mediated MOMP. Because BH3 
proteins selectively interact with a limited spectrum of anti-apoptotic proteins, a 
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combination of BH3 proteins is required to induce apoptosis in cells expressing multiple 
anti-apoptotic Bcl-2 family members (Shamas-Din et al., 2013) (Lalier et al., 2007). 
Other studies showed that pro-apoptotic Bax can be inactivated by Ku70, a DNA repair 
protein, and that Bax is regulated by Ku70-dependent deubiquitynation. In the 
cytoplasm of a normal cell, Bax forms a complex with Ku70, which inactivates Bax 
function. The release of Ku70 from the complex induces a conformational change in 
Bax that allows tBid to bind to Bax. The activated Bax is inserted into the MOM, 
destabilizing it and therefore cells proceed to apoptosis execution (Yonekawa & Akita, 
2008). 
Cytoplasmic Bax can undergo large but reversible conformational changes after 
interacting with the MOM, which increase the affinity for BH3 proteins, causing a further 
conformational change and allowing insertion in the mitochondrial membrane. This 
interaction with BH3 proteins incorporates features from two models: displacement and 
direct activation, because the sensitizer BH3 proteins neutralize the dual function of the 
anti-apoptotic proteins by displacing both the activator BH3 proteins and Bax from the 
membrane-embedded conformers of the anti-apoptotic proteins. Because it is the 
activated form of Bax that is bound to the membrane-embedded anti-apoptotic 
proteins, sensitizer proteins release Bax conformers competent to oligomerize and 
permeabilize membranes (Shamas-Din et al., 2013). 
 
An alternative possibility is that activated Bax/Bak form pores directly in the MOM. 
Amphipathic α-helical peptides can permeate membranes via two separate 
mechanisms, termed barrel-stave or toroidal. In both models, the helices line the pore 
perpendicularly to the membrane. The barrel-stave model creates a proteic pore devoid 
of lipids, while a toroidal pore is composed of protein and lipid components, where Bax 
inserts three amphipathic helices (5, 6, and 9) into the MOM before oligomerization and 
MOMP. Electrophysiological studies identified a pore that was termed the mitochondrial 
apoptosis-induced channel (MAC). MAC contains oligomeric Bax or Bak, providing the 
first indication that these proteins can create a proteic pore (Shamas-Din et al., 2013). 
Since it was identified, Bax has been the subject of many biochemical studies to 
identify its function at the molecular level. It is known that Bax plays a key role in 
apoptosis acting on mitochondrial permeability, however the mechanism of action is not 
yet fully known, since there are other interactions between Bax and other proteins with 
similar functions to the Bcl-2 family, such as the protein kinase C family. 
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1.2.3 The protein kinase C family 
The protein kinase C (PKC) family was discovered in 1977 by Yasutomi Nishizuka, 
and is composed of protein kinases activated by several different substrates (Toton et 
al., 2011). This family of serine/threonine kinases plays key roles in the regulation of 
many cellular processes, including cell cycle, apoptosis, differentiation, angiogenesis, 
multi-drug resistance and senescence; however, how PKCs regulate these processes 
in vivo is not evident, since all the cells or tissues express multiple isozymes of PKC 
(Silva et al., 2012) (Marengo et al., 2011). The PKC family contains at least 12 kinases 
encoded by nine different genes. These can be classified into three different 
subfamilies based on their structure and cofactors required for its activation: classical 
or conventional PKCs (cPKCs: α, βI, βII and ) that require calcium (Ca2+), 
phosphatidylserine and diacylglycerol (DAG) for activation; novel PKCs (nPKCs: ,, 
and ) that require phosphatidylserine, DAG but not Ca2+ and atypical PKCs (aPKCs:  
e /1) which only require phosphatidylserine for their activation (Silva et al, 2012.). 
All isozymes of this family have a conserved carboxyl-terminal tail that serves as a 
phosphorylation-dependent anchoring site for key regulatory molecules and a 
pseudosubstrate sequence that holds PKC in an inactive state.  The V3 region lies 
between the regulatory domain and the catalytic domain, and is accessible to 
proteolytic cleavage by activation and conformational changes of PKCs (Fig.5). 
Cleavage at this site leads to the release of a constitutively active catalytic domain, 
suggesting that many inhibitory intramolecular interactions occur between these 
domains (Marengo et al., 2011). 
 
 Figure 5.  Schematic representation of structure and classification of the family of PKC 
isozymes (Mackay & Twelves, 2007). 
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Members of the PKC family of isozymes differ in their structure and mode of 
activation, but also in their tissue distribution, subcellular localization and substrate 
specificity. Activation of these isozymes results in changes in their subcellular 
localization, followed by the translocation of specific anchoring proteins, called 
receptors of activated C kinase (RACKS) (Mochly-Rosen & Gordon, 1998). 
Other anchoring proteins have been suggested as inactivating PKC isozymes, 
receptors for inactive C-kinase isozymes (RICKS). Mochly-Rosen and colleagues took 
advantage of isoenzyme-specific interactions between PKCs and RACKS to overcome 
the lack of specific activators and inhibitors of PKC isozymes. They developed a 
number of first-generation peptides derived from PKCs or RACKS, based on their 
interaction sites, which interfere with PKC/RACK protein-protein interactions. By the 
same principle, peptides that interfere with the PKC/RICK interaction should act as 
specific agonists of PKCs. The advantages of using these peptides as drugs are their 
flexibility and fit abilty, since they are naturally selected for a particular protein 
interaction site, allowing them to interact more effectively and specifically with proteins 
and interfere with several interaction sites on a protein.  
Some of these peptides, such as a PKCε-activator and a PKCδ-inhibitor have been 
used as pharmacological modulators of PKC activity in animal models of disease and 
in basic research (Wu-Zhang & Newton, 2013). 
 
 
1.2.3.1. Regulation of apoptosis by PKC isoforms 
The activation of PKCs can induce apoptosis in some cell types, while in other 
cases prevents it, making it difficult to predict the role of PKCs in the apoptotic process. 
In general, PKCα, ε, ζ and λ/ι are considered anti-apoptotic, promoting survival and 
proliferation, while PKCδ is characterized as pro-apoptotic, having a tumor suppressor 
role (Reyland, 2009). 
Conventional PKCs prevent cell shrinkage mediated by FAS since they inhibit the 
TRAIL death receptor and in turn aggregation of the FAS receptor, recruitment of 
FADD and DISC formation. In that group, the most studied is the PKCα isoenzyme, 
which has been associated with the intrinsic pathway due to its ability to mediate 
expression and phosphorylation of Bcl-2, leading to an increase in the anti-apoptotic 
function of this protein. PKCα also suppresses drug-induced apoptosis by increasing 
the promoter activity of the multidrug resistance gene (MDR1), and thus the stability 
and expression of P-glycoprotein (Lønne, 2010). 
The role of PKCβ in apoptosis is contradictory. The gene encoding for this protein 
creates two isoforms by alternatively splicing, PKCβI and PKCβII, and several studies 
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have failed to distinguish the contribution of each of these variants to apoptosis. It is 
believed that PKCβII is involved in the prevention of apoptosis, and expression of the 
oncogene v-abl causes translocation of PKCβII to the nucleus, preventing apoptosis, 
and indicating that PKCβII is anti-apoptotic (Gutcher et al., 2003). 
The isoenzymes of the novel PKC subfamily PKCδ and PKCε are the best studied. 
Overexpression of PKCδ stimulates apoptosis in a wide variety of cell types via a 
mechanism that is not completely understood. When this protein is absent, cells are 
unable to respond to DNA damage-induced apoptosis, suggesting that PKCδ is 
required for a response to apoptotic stress (Teicher, 2006). When PKCδ is targeted to 
the cytosol, mitochondria, or nucleus frequently behaves as pro-apoptotic, while PKCδ 
targeted to the ER protected against tumor necrosis factor-related apoptosis, ligand-
induced apoptosis and etoposide-induced apoptosis. PKCε increases the expression of 
anti-apoptotic members of the Bcl-2 family and inhibits proapoptotic members of this 
family, such as Bax and Bad (Sivaprasad et al., 2007). PKCε is the only isoenzyme that 
is considered an oncogene and regulates cancer cell proliferation through cell signaling 
by interacting with three major factors RhoA/C, Stat3, and Akt; however, when PKCɛ is 
activated it has protective roles in cardiac and brain ischemia, nociception and heat 
shock response (Jain & Basu, 2014) (Huang et al., 2011). 
 
1.2.3.2. Protein kinase C epsilon 
As previously mentioned, PKC protein belongs to the subfamily of the novel PKCs, 
whose structure comprises a regulatory N-terminus and a C-terminal catalytic domain 
with four conserved regions (C1-C4) and a variable region (V3) domain (Figure 6). The 
variable domain V3 is the region where the PKC isoforms can be cleaved by caspases 
(Newton, 1995). 
 
 
 
 
 
 
 
After the discovery of PKCε, there have been many studies on the involvement of 
this kinase in cell survival and cell death. Though the majority of the studies suggest 
Figure 6. Structural representation of the PKC protein. Image adapted from Silva et al., 2012 
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that it favors life, some showed that activation of PKCε could contribute to apoptosis. 
PKCε acts as an oncogene with antiapoptotic effects when overexpressed in cancer 
cells, and is also oncogenic in colon epithelial cells through interference with Ras signal 
transduction (Yonekawa & Akita, 2008). Activation of the Ras/Raf/MAP kinase cascade 
results in the transcription of genes involved in cell proliferation and growth. Stimulation 
of Ras results in the translocation of Raf-1 from the cytosol to the plasma membrane 
being activated by a specific set of kinases including PKC (Toton et al., 2011).The 
anti-apoptotic ability of PKC also depends on the increased expression of anti-
apoptotic proteins of the Bcl-2 family and the suppression of pro-apoptotic members 
(Figure 7). Moreover, overexpression of PKC increases activation of nucleophosmin 
(NPM), a phosphoprotein capable of inducing carcinogenesis (Gorin & Pan, 2009). 
PKCε is cleaved by caspases in response to several apoptotic stimuli, including 
chemotherapeutic agents, starvation and TNF. In one study, cleavage of this protein 
was inhibited by inhibitor of caspase-3, and PKCε was cleaved by recombinant human 
caspase-3, suggesting that PKCε is a substrate for this caspase. The results of this 
study suggest that caspase-7 is the major caspase that cleaves PKCε at the Asp383 
site in intact cells (Basu & Sivaprasad, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Regulation of cell proliferation and cell death by PKCε (Basu & Sivaprasad, 2007) 
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The subcellular distribution is an essential feature of activation of PKC. When 
PKC is activated, it inhibits the release of cit c from mitochondria, activation of 
caspases, and suppresses apoptosis. Thus, activation of PKC in mitochondria is 
associated with the suppression of cell death and improved cell survival (Nowak et al., 
2004). To become responsive to second messengers, PKCε requires the 
phosphorylation of three conserved sites: Thr-566 in the activation loop, Ser-729 site in 
the hydrophobic C-terminus, Thr-710 and an autophosphorylation site. The subcellular 
localization of this kinase will depend in part on the second messenger that is 
connected to the C1 domain. Thus, PKC translocates from the plasma and/or 
membrane to the cytoskeleton in response to DAG and tridecanoic acids, or the Golgi 
network in response to arachidonic acid and linoleic acid (Akita, 2002). 
 
 
1.2.3.3. Regulation of Bax by PKC  
The anti-apoptotic properties of PKC appear to involve the regulation of several 
members of the Bcl-2 family, increasing the expression of anti-apoptotic members of 
this family and inhibiting pro-apoptotic members (Silva et al., 2012). Different studies 
show that PKC interacts with several proteins, one of which is pro-apoptotic Bax 
protein, preventing its integration into the mitochondrial membrane. Thus, PKC allows 
the survival of various cancer cells by inhibiting Bax conformational rearrangements 
that are important for its oligomerization, mitochondrial integration and release of cyt c, 
which inhibits cell death. PKC does not contain a similar BH3 domain, and since the 
crystal structure of the protein is not entirely known, it is not possible to predict if it has 
an appropriate interface to directly interact with Bax (McJilton et al., 2003).  
The PKCε protein is an important signaling molecule, and understanding how it 
determines the decision of life or death of a cell will help in understanding the process 
of carcinogenesis and facilitate the identification of new targets for cancer therapy. In 
this project, we aim to understand how the interaction between this protein and Bax 
occurs, so that in the future new drugs to inhibit this interaction and promote cell death 
can be developed. 
 
 
1.3. Yeast as a powerful model to study the regulation of Bax  
The yeast Saccharomyces cerevisiae has already been used as a tool to 
understand molecular mechanisms of apoptotic pathways, such as the complexities of 
the function of Bcl-2 family members. The initial observation that the expression of Bax 
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confers a lethal phenotype in yeast was made during yeast-two-hybrid studies to 
analyze interactions between Bax and Bcl-2. These results prompted the hypothesis 
that the mammalian Bcl-2 proteins act on elements of a conserved endogenous yeast 
machinery to mediate effects on cell viability, and suggest that Bax-mediated cell death 
in yeast involves a regulated insertion into mitochondrial membranes and mitochondrial 
dysfunction leading to the release of cyt c and apoptosis, supporting the hypothesis 
that Bax exerts effects in yeast that are comparable to mammalian cells (Khoury & 
Greenwood, 2008). Manon and his team suggest that, in yeast cells, Bax induces 
growth arrest due to defects in the respiratory chain such as a decrease in the amount 
of the cyt c oxidase (COX) complex and the release of cyt c to the cytosol (Ludovico et 
al., 2005). Priault et al also demonstrated that Bax-c-myc induces a massive release of 
cyt c in yeast ; the observation that wild-type Bax is unable to induce the cyt c release 
and yeast cell death, confirm the central role of mitochondria in apoptosis (Priault et al., 
2003). 
 
Expression of Bax induces hyperpolarization of mitochondria, production of reactive 
oxygen species (ROS), cyt c release and mitochondrial network fragmentation 
reinforcing the importance of mitochondria in Bax-induced death (Silva et al., 2011) 
In yeast, there are no known obvious orthologs of Bcl-2 family members; however 
the core components of the mammalian PTP are highly conserved in eukaryotic 
organisms. Almost all the studies concerning the role of PTP components in death and 
mitochondrial permeabilization in yeast have been performed in cells heterologously 
expressing the pro-apoptotic Bax protein; however, some data suggest that the PTP 
components do not exhibit a significant role in Bax-induced cell death (Pereira et al., 
2008). In fact, was discovered that yeast cells lacking cyt c still die after Bax 
expression, although at a slower rate, indicating that cyt c release is not essential for 
Bax-induced cell death (Priault et al., 1999a). 
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The residues of PKC required for interaction with Bax were never identified. This 
information is crucial to direct screening of libraries of compounds with affinity for the 
key residues in the interaction sites to specifically disrupt the PKC /Bax interaction. 
 
The aim of this study was to identify the PKC residues required for interaction with 
Bax, using the following approaches: 
 
1. Assess which domains of PKCε interact with Bax by immunoprecipitation and 
Yeast-two-hybrid 
2. Identify which residues could be involved in this interaction by single 
substitution of selected residues. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5. Materials and 
Methods 
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1.5.1. Yeast strains and growth conditions 
All strains used in this study are listed in Table I.  
For Yeast-two-hybrid (YTH), the PJ69-4a strain was used (Figure 8). This strain 
has three reporter genes under the control of distinct GAL4 upstream activating 
sequences (UASs) and TATA boxes (ADE2, HIS3, and lacZ). These promoters yield 
strong and specific responses to GAL4. As a result, two major classes of false positives 
are eliminated: those that interact directly with the sequences flanking the GAL4 
binding site and those that interact with transcription factors bound to specific TATA 
boxes. 
 
 
Figure 8. The classical YTH system. The protein of interest is fused to the DNA binding domain 
(DBD), a construct called bait. The potential interacting protein is fused to the activation domain (AD) and 
is called prey. The bait binds the upstream activator sequence (UAS) of the promoter. The interaction of 
bait with prey recruits the AD and thus reconstitutes a functional transcription factor, leading to further 
recruitment of RNA polymerase II and subsequent transcription of a reporter gene. 
 
 
Table I. List of strains used in this study. 
Strain Genotype Reference 
XL1 blue Δ(mcrA)183  Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac [F′ proAB lacI
q
ZΔM15 Tn10 (Tet
r
)] 
Stratagene 
W303-1A MATa, leu2-3, ura3-1, trp1-1, his3-11, ade2-
1, can1-100 
(Rothstein, 1983) 
 
PJ69-4a 
MATa trp1-∆901 leu2-3,112 901  
ura3-52 his3-∆200 gal4∆ gal8∆ 
GAL2-ADE2 LYS2::GAL1-HIS3  
met2::GAL7-lacZ 
 
 
(James et al., 1996) 
 
pGAD
_PKC 
Transcription 
DBD 
pGBKT7
_Bax 
UAS Promoter 
AD 
   Reporter Gene 
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W303-1A pGAD_PKC W303-1A harboring pGAD_PKC This study 
XL1 blue  pGBKT7_Bax XL1 blue harboring pGBKT7_Bax This study 
PJ69-4a  pGBKT7_Bax 
pGAD_PKC 
PJ69-4a  harboring pGBKT7_Bax and 
pGAD424_PKC 
This study 
PJ69-4a  pAS2_Kap120 
pGAD_PKC 
PJ69-4a  harboring pAS2_Kap120 and 
pGAD424_PKC 
This study 
PJ69-4a  pGBKT7 pGAD_Ran PJ69-4a  harboring pGBKT7 and 
pGAD_Ran 
This study 
 PJ69-4a  pGBKT7 pGAD_PKC PJ69-4a  harboring pGBKT7 and 
pGAD424_PKC 
This study 
PJ69-4a  pAS2_Kap120 
pGAD_Ran 
PJ69-4a  harboring pAS2_Kap120 and 
pGAD_Ran 
This study 
W303-1A pYES3 pESC-His W303-1A harboring pYES3 and pESC-His This study 
W303-1A pYES3 pESC-His C1 W303-1A harboring pYES3 and pESC-His 
C1 
This study 
W303-1A pYES3 pESC-His C2 W303-1A harboring pYES3 and pESC-His 
C2 
This study 
W303-1A pYES3 pESC-His Kin W303-1A harboring pYES3 and pESC-His 
Kin 
This study 
W303-1A pYES3 pESC-His 
PKC 
W303-1A harboring pYES3 and pESC-His 
PKC 
This study 
W303-1A pYES3_Baxwt  pESC-
His C1 
W303-1A harboring pYES3_Baxwt and 
pESC-His C1 
This study 
W303-1A pYES3_Baxwt  pESC-
His C2 
W303-1A harboring pYES3_Baxwt and 
pESC-His C2 
This study 
W303-1A pYES3_Baxwt  pESC-
His Kin 
W303-1A harboring pYES3_Baxwt and 
pESC-His Kin 
This study 
W303-1A pYES3_Baxwt  pESC-
His PKC 
W303-1A harboring pYES3_Baxwt and 
pESC-His PKC 
This study 
W303-1A pYES3_Baxwt  pESC-
His 
W303-1A harboring pYES3_Baxwt and 
pESC-His 
This study 
W303-1A pYES3 YEplac181 W303-1A harboring pYES3 and YEplac181 This study 
W303-1A pYES3 
YEplac181_PKC 
W303-1A harboring pYES3 and 
YEplac181_PKC 
This study 
W303-1A pYES3_Baxwt 
YEplac181 
W303-1A harboring pYES3_Baxwt and 
YEplac181 
This study 
W303-1A pYES3_Baxwt 
YEplac181_PKC 
W303-1A harboring pYES3_Baxwt and 
YEplac181_PKC 
Silva R. 
 
 
Strains were transformed with the indicated plasmids using the lithium acetate 
method as described in section 1.5.3. Transformants were selected on Synthetic 
Complete medium [SC: 0.17% (w/v) Yeast nitrogen base without aminoacids and 
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ammonium sulfate, 0.5% (w/v) ammonium sulfate, 0.14% (w/v), drop-out mixture 
lacking histidine, leucine, tryptophan and uracil, 0.008% (w/v) Histidine, 0.04% (w/v) 
Leucine, 0.008% (w/v) Tryptophan and 0.008% (w/v) Uracil] lacking the appropriate 
aminoacids plus 2% (w/v) of carbon source and 2% agar. Yeast strains were 
maintained on solid Yeast extract peptone dextrose (YPD) or Synthetic complete (SC) 
medium (lacking the appropriate aminoacids), grown at 30°C for 48h-72h, stored at 
4°C, and refreshed every 2-3 weeks. Yeast cultures were grown aerobically in SC 
medium with 2% Glucose or Galactose as a carbon source or anaerobically in SC 
medium with 2% Lactacte pH 5.5. Strains transformed with plasmids were grown in SC 
medium lacking the appropriate aminoacids. Cells were incubated at 30°C with orbital 
shaking (200 rpm) and a liquid/air ratio of 1:5. 
 
 
1.5.2. Plasmids 
All the plasmids and oligonucleotides used in this study are listed in Tables II and 
III, respectively. The vector used to express Bax was pGBKT7 (Clontech). The 
pGBKT7 vector expresses proteins fused to amino acids 1–147 of the GAL4 DNA 
binding domain (DNA-BD). This vector also has other characteristics which make it 
suitable for use in the YTH system, such as two independent origins of replication in 
bacteria and yeast, the Kanamycin resistance for selection in E. coli and the TRP1 
auxotrophic marker for selection in yeast. It also has a multiple cloning site (MCS) for 
insertion of the DNA fragment under consideration. 
The vector used to clone PKC was pGAD424 (Clontech). pGAD424 is a shuttle 
vector that replicates autonomously in both E. coli and S. cerevisiae and generates a 
hybrid protein that contains the sequences for the GAL4 activation domain (DNA-AD). 
It carries Ampicillin resistance for selection in E. coli and the LEU2 auxotrophic marker 
that allows yeast auxotrophs carrying pGAD424 to grow on limiting synthetic medium 
lacking Leucine (LEU). 
 
 
             Table II. List of plasmids used in this study. 
Plasmid Description Reference 
pGBKT7 TRP1; KanR Clontech 
pGBKT7_Bax wt Bax wt inserted in pGBKT7 This study 
pGAD424 LEU2;AmpR Clontech 
pGAD424_PKC PKC inserted in pGAD424 This study 
pYES3 TRP1; AmpR Invitrogen 
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YEplac181 LEU2;AmpR (Gietz & Sugino, 1988) 
YEplac181_PKC PKC inserted in YEplac181 Nigel Goode 
pESC-HIS HIS3;AmpR Agilent 
pYES3_Bax wt Bax wt inserted in pYES3 Silva R. 
pESC-HIS_C1 C1 inserted in pESC-HIS  Vieira S. 
pESC-HIS_C2 C2 inserted in pESC-HIS Vieira S. 
pESC-HIS_KIN KIN inserted in pESC-HIS Vieira S. 
pESC-HIS_PKC PKC inserted in pESC-HIS Vieira S. 
pAS2_Kap120 Kap120 inserted in pAS2 Chaves S. 
pGAD_Ran Ran inserted in pGAD Chaves S. 
 
 
Table III. List of oligonucleotides used in this study. 
Number Name Oligonucleotide sequence 
1 pAS2-1_BaxFw 5´-AAAGACAGTTGACTGTATCGCCGGAATTCATGGACGGT 
TCCGGTGAACAA-3´ 
2 pAS2-1_BaxRv 5´- ATTCGCCCGGAATTAGCTTGGCTGCAGTCAACCCATCT 
TCTTCCAGATGG-3´ 
3 pGAD_PKCFw 5´-ACCCAAAAAAAGAGATCGAATTCATGGTAGTGTTCAAT 
GGCCTTCTTAAG-3´ 
4 pGAD_PKCRv 5´-ATCTACGATTCATAGATCTCTGCAGTTAGGGCATCAGG 
TCTTCACCAAA-3´ 
5 pAS2_seq_F 5´-TCATCGGAAGAGAGTAGTAACAAAGG-3´ 
6 M13Rv 5´-TCCTGTGTGAAATTGTTATCCGCT-3´ 
7 pGAD_seq_F 5´-CACTACAGGGATGTTTAATACCACTAC-3´ 
8 pGAD_seq_R 5´-GTTCACTTCAACTGTGCATCGT-3´ 
 
 
pGBKT7_Bax was constructed by standard ligation (Figure 9).  Briefly, the Bax 
gene was amplified by PCR using pYES2_Baxwt (URA) as a template and the PCR 
product was purified using a DNA Clean & ConcentratorTM -5 Kit (Zymo Research) 
according to manufacturer’s instructions. The pGBKT7 vector and purified Bax were 
digested with EcoRI and PstI and the digestion product was purified using a DNA 
Clean & ConcentratorTM -5 Kit (Zymo Research) in order to remove the endonucleases. 
Ligation was performed using 1l of vector DNA, 10l of insert DNA, 2l of 10X Ligase 
Buffer, 1l of T4 DNA ligase and H2O to a total volume of 20l, and the reaction was 
incubated at 4ºC overnight. 10l of reaction were transformed into E. coli XL1 Blue, 
and cells plated on Luria Bertani medium [LB; 1% (w/v) Tryptone, 0.5% (w/v) Yeast 
extract, 1% (w/v) NaCl and 2% (w/v) Agar] supplemented with 100 μg/mL Kanamicin. 
The plasmid was then extracted from E. coli using the GenElute Plasmid Miniprep kit 
(Sigma-Aldrich) and correct integration of the insert was confirmed by restriction 
analysis, PCR using oligonucleotides 5 and 6, and sequencing.  
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The pGAD-PKC clone was constructed in W303-1A by homologous recombination 
(Figure 10). The gene encoding the protein was amplified by Polymerase Chain 
Reaction (PCR) using the oligonucleotides listed in Table III (numbers 3-4), and co-
transformed in yeast with cut pGAD424 through the lithium acetate method (described 
in section 1.5.3). After growth on SC medium (lacking the appropriate aminoacids) at 
30°C for 48h, genomic DNA was extracted from putative positive clones and amplified 
in E. coli XL1 Blue by transformation using standard procedures and selection on LB 
supplemented with 100 μg/mL Ampicillin. The plasmid was then extracted from E. coli 
using the GenElute Plasmid Miniprep kit (Sigma-Aldrich) and correct integration of the 
insert was confirmed by restriction analysis and PCR using oligonucleotides 7/8 and by 
sequencing. 
 
Figure 9.  Schematic representation of the methodology used to construct pGBKT7-Bax. 
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Figure 10. Schematic representation of the methodology used to construct pGAD424-PKC. 
 
 
1.5.3. Yeast transformation by the lithium acetate method 
All transformations in yeast strains were performed using  the lithium acetate 
method. 240l of 50% (w/v) Polyethylene Glycol (PEG), 36l of 1 M LiAc, 40l of 2 
mg/ml salmon sperm DNA (ssDNA) and 36l (water + plasmid DNA) were mixed, 
vortexed, and 50l of competent yeast cells were added. Then, the mix was incubated 
at 30ºC for 20 minutes, heat shocked for 30 minutes at 42°C and cooled on ice.  
Cells were pelleted by centrifugation at 5000 rpm for 3 minutes, and the pellet was 
resuspended in 100uL of water. The total cell suspension (100L) was plated on 
appropriate selection medium consisting of SC medium supplemented with all essential 
aminoacids, except for the aminoacids of selectable markers on each plasmid and 
incubated at 30°C until the appearance of colonies. 
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1.5.4. Growth curves  
Yeast strains W303-1A pYES3 pESC-His, W303-1A pYES3 pESC-His C1, W303-
1A pYES3 pESC-His C2, W303-1A pYES3 pESC-His Kin, W303-1A pYES3 pESC-His 
PKC, W303-1A pYES3_Baxwt  pESC-His C1, W303-1A pYES3_Baxwt  pESC-His C2, 
W303-1A pYES3_Baxwt  pESC-His Kin, W303-1A pYES3_Baxwt  pESC-His PKC, 
W303-1A pYES3_Baxwt  pESC-His, W303-1A pYES3 YEplac181, W303-1A pYES3 
YEplac181_PKC, W303-1A pYES_Baxwt YEplac181 and W303-1A pYES_Baxwt 
YEplac181_PKC were first grown in SC medium with 2% of glucose lacking the 
appropriate aminoacids. Cells were then transferred to SC medium with 2% of 
Lactacte, pH 5.5, and grown to an O.D (640nm) of 0.3-0.5 (exponential phase). Then, 
2% of galactose was added to induce PKC and Bax expression. The growth of yeast 
strains was assessed at different times. All incubations were performed at 30°C, 200 
r.p.m. 
 
 
1.5.5. Analysis of protein expression 
1.5.5.1.  Preparation of protein extracts  
For detection of protein expression by Western blot of total cellular extracts, 5mL 
of cell culture were grown in SC medium with 2% of glucose and were then transferred 
to SC medium with 2% of galactose for 16h. Cells were harvested at an O.D (640nm) 
of 1, and resuspended in 1ml of H2O. After centrifugation at 5000 rpm for 3 min, the 
pellet was suspended in 500l of H2O and 50l of a mixture of 3.5% β-mercaptoethanol 
in 2M NaOH was added. After 15 min incubation on ice, proteins were precipitated with 
50l of 50% (w/v) trichloroacetic acid (TCA) for 15 min on ice. Following centrifugation 
at 10000 g for 10 min, the pellet was solubilized in 1x Laemmli Buffer (63mM Tris-HCl 
pH 6.8; 10% glycerol; 0,0005% bromophenol blue; 2% SDS and 0.1M DTT) and the 
samples were boiled at 100ºC for 5 min in order to denature proteins. 
 
 
1.5.5.2. SDS gel electrophoresis/Western blot 
Total cellular extracts were separated electrophoretically in a 15% SDS 
polyacrylamide gel at 25 mA and transferred to a Hybond-P Polyvinylidene Difluoride 
Membrane (PVDF) (Hybond-ECL, GE Healthcare) at 60 mA for 1 h and 30 min. 
Membranes were blocked for 1h in PBS-T [80 mM Na2HPO4, 20 mM NaH2PO4 and 
100 mM NaCl with 0.05% (v/v) Tween-20] containing 5% (w/v) non-fat dry milk, washed 
in PBS-T and then cut into strips and incubated with the primary antibodies: mouse 
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monoclonal anti-yeast phosphoglycerate kinase (PGK1) antibody (1:5000, Molecular 
Probes), rabbit polyclonal anti-human Bax (BAX) antibody (1:5000, Sigma), mouse 
anti-FLAG antibody (Sigma) and rabbit polyclonal anti-human PKC (PKC) antibody 
(1:100, Santa Cruz Biotechnology). Then, membranes were incubated with IgG-
peroxidase secondary antibodies against mouse or rabbit (1:5000; Sigma Aldrich). 
Pgk1p was used as a loading control. Immunodetection of bands was revealed by 
chemiluminescence (Chemidoc XRS, BioRad). 
 
 
1.5.6. Immunoprecipitation 
Imunoprecipitation was performed using protein G-coupled Dynabeads 
(Invitrogen). Cells were ressuspended in resuspension buffer (10 mM Tris–malate, 0.6 
M Mannitol, 1 mM EGTA, pH 6.7) supplemented with a mixture of protease inhibitors 
(0.4 μl/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mM phenylmethylsulfonyl 
fluoride and phosphatase inhibitors (PhosSTOP phosphatase inhibitor cocktail tablets; 
Roche Applied Science)). Cells were broken mechanically by vortexing with glass 
beads, after which 10× IP buffer (1x IP buffer: 50mM Tris-HCl, pH7.5; 100mM NaCl; 
2mM EDTA) was added to the cell lysate to a final concentration of 1x, and incubated 
at 4 °C during 1 h.  After incubation with IP buffer, 2 μg of monoclonal anti-FLAG 
antibody (Sigma) was added, and the lysate incubated overnight at 4 °C. Protein G-
coupled Dynabeads (Invitrogen) were added and the extracts incubated for 6 h. 
Washing was performed with 1x IP buffer and elution was performed with Laemmli 
sample buffer, followed by denaturing at 65ºC for 30 min.  
 
 
1.5.7. Yeast-two-hybrid  
To verify the interaction between Bax and PKC proteins, pGBKT7_Bax and 
pGAD_PKC vectors were transformed into strain PJ69-4a, as well as various negative 
controls: pAS2_Kap120-pGAD424_PKC, pGBKT7-pGAD_Ran and pGBKT7-
pGAD424_PKC  and a positive control tested before: pAS2_Kap120-pGAD_Ran. 
The cells were plated on appropriate selection medium supplemented with all 
essential aminoacids, except tryptophan and Leucine (SD -TRP-LEU), and incubated 
at 30°C until the appearance of colonies. 
In order to assess whether the proteins studied are independently capable of 
activating transcription of the reporter genes or interact with each other, isolated 
colonies of the yeast strain PJ69-4a pre-transformed with the plasmids mentioned 
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above were plated on SD -TRP-LEU-HIS and  SD -ADE-TRP-LEU). These colonies 
were also tested for the expression of -galactosidase (lacZ gene product) by X-Gal (5-
bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside) filter-assay as described in 
(Mockli & Auerbach, 2004). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6. Results 
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1.6.1. Previous Results 
Before this study, the DNA sequence coding for PKCε was cloned in the pESC-
HIS plasmid, in frame with the FLAG epitope, and transformed into a W303-1A strain 
expressing Bax. Then, Bax was immunoprecipitated from extracts from this strain with 
the Bax-2D2 antibody, bound proteins run on an SDS-PAGE gel, transferred to PVDF 
and probed with an anti-PKC antibody in order to verify whether PKC and Bax 
interact in yeast (Figure 11A, B). 
 
          A                                                               B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Immunoprecipitation of Bax-interacting proteins. Lysates from cells expressing Bax and 
PKC were immunoprecipitated with Bax antibody (2D2). Bound proteins were eluted with loading buffer, 
denaturated at 65ºC for 30min, run on SDS-PAGE and transferred to PVDF. Western blots were 
performed with anti-Bax antibody (A) and anti-PKC antibody (B).  C+ WB:anti-Bax was W303-1A pYES3-
Baxwt and C+ WB:anti-PKC was W303-1A YEplac181-PKC pYES3-Baxwt in order to verify expression 
of Bax and PKC, respectively. 
 
 
However, PKC was not detected in the immunoprecipitated extract, and 
therefore an interaction between full length PKC and Bax could not be demonstrated 
in yeast.  
 
 
 
 
IP: α-Bax 
WB: anti-Bax 
IP: α-Bax 
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1.6.2. Effect of expressing Bax and different PKC fragments on cell growth  
Yeast has been considered an important tool to discover the different cellular 
targets of several proteins. Moreover, the preservation of functional characteristics of 
mammalian PKCs in yeast led to the identification and characterization of the mode of 
action of several PKC modulators in yeast cells expressing individual PKC isforms 
(Sprowl et al., 2007). It had previously been shown that expression of PKC reverted 
the slow growth phenotype of yeast cell expressing Bax, indicating PKC could function 
as an inhibitor of Bax, presumably by protein-protein interaction (R. Silva, personal 
communication). This could be a transient or weak interaction, and therefore not 
detected in the immunoprecipitation studies. We therefore sough to determine whether 
one or more domains of PKC had the same effect of the growth of Bax-expressing 
cells. 
In this study, full length and individual domains of PKC (C1, C2, Kinase) cloned 
in pESC-His (S. Vieira) were transformed in the W303-1A yeast strain expressing Bax. 
We next sough to identify which of these domains could be involved in the interaction 
with Bax by determining if they caused a reversal of the slow growth phenotype of cells 
expressing Bax (Figure 12 A, B, C, D and E). 
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Figure 12. Growth curves of the S. cerevisiae strain W303-1A expressing the indicated proteins 
induced by galactose at T0. (A)- Growth curves for yeast strain W303-1A carrying C1 domain (pC1) and 
empty vector of Bax (pYES3) (); pC1 plus pBax (); empty vector of PKC (pESC-His) plus pYES3 () 
and pESC-His plus pBax(). (B)- Yeast strain W303-1A carrying C2 domain (pC2) and pYES3 (); pC2 
plus pBax (); pESC-His plus pYES3 () and pESC-His plus pBax(). (C)- Yeast strain W303-1A carrying 
Kinase domain (pKin) and pYES3 (); pKin plus pBax (); pESC-His plus pYES3 () and pESC-His plus 
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pBax(). (D)- Yeast strain W303-1A carrying PKC protein (pPKC) and pYES3 (); pPKC plus pBax (); 
pESC-His plus pYES3 () and pESC-His plus pBax().  (E)- Specific growth rates (h
-1
) of W303 cells 
expressing the indicated proteins.  Empty plasmids used as a control. These data result from the mean of 
three independent experiments. Specific growth rate was calculated using the formula = lnX - lnX0 
                                                                                                                                         t-t0 
 
 
Analyzing the data obtained, it appears that there is no reversal in the slow 
growth phenotype of Bax-expressing cells by PKC protein. Only expression of the 
PKC-Kinase domain partially reverts the slow growth phenotype of Bax-expressing 
cells. These results are not in agreement with previous data from the lab (R. Silva, 
unpublished data). We therefore decided to study the growth phenotype of the W303-
1A strain expressing Bax and PKC from the same plasmids used in the previous 
study, i.e. YEplac181 instead of pESC-HIS to express PKC (Figure 13 A and B). In 
this case, expression of PKC is able to partially revert the slow growth phenotype of 
the W303-1A strain expressing only Bax. 
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       B                                                                       
 
 
 
 
 
 
 
 
Figure 13. Growth curves of the S. cerevisiae strain W303-1A expressing the indicated proteins 
induced by galactose at T0. (A)- Growth curves for yeast strain W303-1A carrying PKC protein (YPKC) 
and empty vector of Bax (pYES3) (); YPKC plus pBax (); empty vector of PKC (YEplac181) plus 
pYES3 () and YEplac181 plus pBax (). (B)-  Specific growth rates (h
-1
) of W303 cells expressing the 
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indicated proteins. Empty plasmids were used as a growth control. These data result from the mean of 
three independent experiments. Specific growth rates was calculated using the formula = lnX - lnX0 
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Previous studies by Silva et al. (2012) found that PKCε leads to Bax 
dephosphorylation and inhibits translocation of Bax into mitochondria. They 
hypothesized that an interaction between these two proteins in yeast would probably 
prevent Bax phosphorylation by endogenous yeast kinases by blocking their access to 
Bax, and would also retain Bax in the cytosol, which would be in agreement with the 
data from the growth curves. 
In order to understand why expression of PKC from different plasmids led to 
opposing results, we determined if its levels differed. Western blot of whole cell extracts 
from strains W303-1A pESC-HIS PKC-FLAG pYES3-Bax and W303-1A YEplac181-
PKC pYES3-Bax shows that the strain expressing FLAG-tagged PKC from pESC-
HIS has much higher levels of PKC than the strain expressing untagged PKC from 
YEplac 181 (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Western Blot of total cellular extracts of S. cerevisiae strains W303-1A pPKC pBax 
and W303-1A YPKC pBax. Anti-PKC and anti-Bax  antibodies were used to detect expressing of PKC 
and Bax, respectively. Anti-PGK was used as a control. 
 
  
Expression of Bax appears to be the same in both strains, so a possible 
explanation for the growth curve differences is that the increased expression of PKC 
protein causes increased toxicity and results in a slow growth phenotype, masking any 
positive effects on cell growth from its presumed interaction with Bax. 
 
 
Bax 
Pgk1p 
PKC 
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1.6.3. Analysis of the interaction between the Kinase domain of PKC and Bax 
by immunoprecipitation  
Since the PKC-Kinase domain partially reverts the slow growth phenotype of 
Bax-expressing cells, immunoprecipitation was performed to detect whether there is an 
interaction between these 2 proteins (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Co-Immunoprecipitation (IP) between PKC-Kin Flag and Bax. IP of the Kinase 
domain was performed with an anti-FLAG antibody and Bax and Kin proteins detected with an anti-Bax or 
anti-FLAG antibody by Western Blot. 
 
 
As shown in Figure 15, Bax was only detected in total extracts and in the 
unbound proteins (after the IP with an anti-FLAG antibody). Therefore, we could not 
detect an interaction between this domain and Bax by IP. This can indicate that the 
interaction between the kinase domain and Bax may be indirect, weak or transient; 
hence it was not possible to verify an interaction by this technique. 
 
 
1.6.4. Analysis of the interaction between PKC and Bax by Yeast-two-hybrid  
The protein interactions play a crucial role in almost of biological processes, from 
DNA replication, transcription, polyadenylation, splicing, transport or translation. 
Currently, it is estimated that more than 80% of the proteins are in active protein 
complexes (Berggard et al., 2007). The yeast two hybrid system (YTH), is one of the 
most used methods to identify interactions between proteins, mainly because it is 
simple to implement and is a good approximation of the in vivo environment of higher 
eukaryotes (Van Criekinge & Beyaert, 1999). 
 
The genes encoding the proteins Bax and PKC were amplified by PCR and then 
cloned into the vectors pGBKT7 and pGAD424, respectively. Correct insertion of the 
- - 
+ 
+ 
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Bax and PKC genes into the plasmids was confirmed by restriction analysis and PCR 
(Figure 16A and B). 
 
           A                                                               B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Confirmation gel of Bax and PKC gene obtained by PCR using oligonucleotides 1, 2, 
3 and 4, respectively (see Table III) and digestion of plasmids. (A)- Confirmation of the correct insertion of 
Bax in the pGBKT7 plasmid by digestion the empty plasmid (pGBKT7) and one Bax clone (pGBKT7_Bax)  
using EcoRV and SalI enzymes, and confirmation by PCR using oligonucleotides 5 and 6. (B)- 
Confirmation of the correct insertion of PKC in the pGAD424 plasmid by PCR using oligonucleotides 7 
and 8. 
 
 
After confirming the correct insertion of genes, the plasmids were sequenced to 
confirm that there was no mutation that could affect the function of each protein. We 
then determined whether there is an interaction between them by YTH, as mentioned 
in the 1.5.7. section. 
As described before, in addition to cells expressing pGBKT7_Bax and 
pGAD_PKC, we used a previously tested positive control, and several negative 
controls. Cells were plated on SC-TRP-LEU, after which they replicated onto agar 
medium without adenine or without histidine, and lifted to filter paper for the X-gal 
assay (reporter genes) (Figure 17 A and B). As seen in Figure 17A and B, only the 
positive control used in this assay grows in both media, and turned blue in the X-Gal 
assay before the negative controls (not shown). Thus, we conclude that PKC and Bax 
do not interact in the yeast nucleus, or that the fusion tags prevent these proteins from 
interacting. 
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Figure 17. Test self-activating protein reporter genes. Activation of the reporter genes HIS3 
and ADE2 was evaluated by the ability of tranformants to grow on plates lacking Adenine (A) or Histidine 
(B). 1- pGBKT7_Bax pGAD_PKC; 2- pAS_Kap120 pGAD_Ran; 3- pAS_Kap120 pGAD_PKC; 4- 
pGBKT7 pGAD_Ran; 5- pGBKT7 pGAD_PKC to grow on media lacking adenine (B) and histidine (C) (-
Ade and -His). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7. Discussion and Future 
perspectives 
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Several studies have reported that Bax and PKC can interact, leading to higher 
survival of cells exposed to apoptotic stimuli. McJilton et al. showed that PKC 
selectively interacts with Bax in the lymph node of prostate carcinoma and suppresses 
the apoptotic effects of phorbol 12-myristate 13-acetate (PMA). They hypothesized that 
this interaction can promote cell survival of prostate carcinoma and block PMA-induced 
apoptosis (McJilton et al., 2003). These results suggested that an interaction between 
Bax and PKC inhibits Bax conformational rearrangements that are important for Bax 
oligomerization, mitochondrial integration, and cyt c release. Lu et al. (2007) 
demonstrated in MCF-7 breast cancer cells that overexpression of PKC inhibited Bax 
dimerization and mitochondrial translocation in response to TNF. They showed that 
Bax is required for TNF-mediated cell death in MCF-7 cells and that overexpression of 
PKC protected MCF-7 cells from TNF-induced mitochondria. 
 
In this study, yeast was used to verify the interaction between PKC and Bax, in 
order to later uncover how to modulate it. Yeast was chosen for this study because it 
has been a powerful tool to uncover the molecular aspects of several biological 
processes, including the apoptotic cascade involving mitochondria and several aspects 
of Bax function. It is particularly relevant that this organism does possess obvious 
homologues of the mammalian Bcl-2 family proteins, so it becomes easier to study 
them individually without the interference from other mammalian apoptotic modulators. 
In addition, the preservation in yeast of the molecular and biochemical functions of 
mammalian PKCs allowed identifying and characterizing some aspects about the mode 
of action of PKC. This favors the use of this simpler model system to identify some of 
the functions of this family (Silva, 2012). 
 
We first performed an in vivo assay based on growth of yeast cells expressing 
Bax and PKC or its domains in order to assess which domains of PKC potentially 
interact with Bax, reversing the slow growth phenotype of Bax-expressing cells. The 
results obtained (Figure 12) demonstrated that the PKC-Kinase domain partially 
reverts the slow growth phenotype of Bax expressing cells, but so far no interaction 
was detected in vitro by co-immunoprecipitation (Figure 15). However, PKC-FLAG did 
not revert the slow growth phenotype of Bax-expressing cells, in agreement with 
previous results of S. Vieira indicating that no interaction between these proteins was 
detected in vitro, but contrasting those obtained by Silva (unpublished data), who 
showed that PKC partially reverts the slow growth of Bax expressing cells (Figure 13). 
The difference between these studies was the vector in which PKC was cloned. In this 
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study, we used the pESC-His vector, a yeast episomal plasmid designed for 
expression and functional analysis of eukaryotic genes in the yeast S. cerevisiae. This 
vector contains the GAL1 and GAL10 promoters in opposite orientation and one or two 
cloned genes can be introduced into a yeast host strain. A sequence for the FLAG 
epitope (DYKDDDDK) is located in the multiple cloning site (MCS) downstream of the 
GAL10 promoter. In the previous study, the vector YEplac181 was used. The main 
difference between these two vectors is the tag (FLAG epitope). As indicated by the 
Figure 14, PKC presents higher levels of expression from the pESC-HIS vector than 
from vector YEplac181.This may be due to a high percentage of galactose (2%) and 
the induction time (16h) used. In the future a lower percentage of galactose in a shorter 
time should be used to induce expression of PKC-FLAG comparable to that of 
untagged PKC from the YEPlac181 vector.  
 
The next step was to use the YTH technique to verify the interaction between the 
two proteins, since it can detect weak or transient interactions that occur in vivo. The 
YTH system offers several advantages over other biochemical methods, including cost, 
simplicity and sensitivity. Still there are some problems that have been associated with 
it. It is assumed that the main disadvantage of the system is the high number of false 
positives in screens, though they can be identified in subsequent steps with proper 
controls (von Mering et al., 2002). It is also possible there are false negatives, because 
certain protein interactions are not reproducible in a YTH environment (Stellberger et 
al., 2010).  
In this study, we could not determine that PKC and Bax do interact in yeast, since 
the strain expressing these proteins did not grow on plates without His and Ade (Figure 
17). This could indicate these proteins do not interact, that the tags used with this 
technique interfere with the interaction, or that they do not interact in the nucleus. 
Indeed, McJilton et al. demonstrated that PKC is associated with numerous proteins 
and the interaction between PKC and Bax probably is indirect and mediated by one or 
several of the intermediate proteins, which may not be present in the nuclear 
environment. A technical alternative to standard YTH would be the split-ubiquitin two 
hybrid system, which can detect interactions between proteins in the cytosolic 
environment, but is technically very challenging. 
 
In order to verify an indirect interaction between Bax and PKC, it would also be 
interesting to use an active form of Bax and isolate the mitochondrial and cytosolic 
fraction of yeast cells to verify the location of Bax and release of cyt c. Using this 
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approach, if Bax and PKC interact in yeast, Bax cannot oligomerize and be inserted in 
the outer mitochondrial membrane, remaining into the cytosol, and there will be no 
release of cyt c. 
 
McJilton et al. (2003) shows through co-immunoprecipitation assays using a 
specific cancer cell line that PKC binds to Bax, and Bax binds to PKC in LNCaP cells. 
Therefore, this cell line could be used in future studies to scan for interactions between 
PKC domains and Bax. 
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2. Introduction 
 
2.1. Nt-acetyltransferases 
Post-translational modifications, including phosphorylation, acetylation and 
others, influence protein function and localization (Yasuda et al., 2013) (Helbig et al., 
2010). Protein acetylation is an important modification, significant in several cellular 
processes and cancer development. One of the most common modifications of proteins 
in mammals is N-α-acetylation of the amino terminus during de novo protein synthesis 
by N-acetyltransferases (NATs), and is found in 50–70% of yeast proteins and 80–90% 
of human proteins (Ferrandez-Ayela et al., 2013). Although for majority of proteins its 
exact biological role has remained enigmatic, in a small number of proteins Nt-
acetyation was linked to modulation of various features such as localization, stability 
and protein-protein interactions. It is therefore considered one of the most important 
post-translational modifications. 
 
NATs transfer an acetyl group from acetyl-coenzyme A (Ac-CoA) to the N-terminus 
of the first amino acid residue of a protein (Figure 18). The acetylated amino acid is the 
initial methionine or the second residue after methionine is cleaved off by methionine 
aminopeptidase. Several specific molecular functions for Nt-acetylation have been 
uncovered, such as regulation of protein degradation, prevention of protein 
translocation from the cytosol to the ER, mediation of protein complex formation and 
membrane attachment of small GTPases involved in organelle trafficking (Starheim et 
al., 2012). Some studies showed that the catalytic subunits of NATs can also catalyze 
N--acetylation, which is the acetylation of e-lysine groups on internal sites of proteins, 
suggesting that they have functions besides the co-translational Nt-acetyltransferase 
activity (Kalvik & Arnesen, 2013). 
 
 
Figure 18.  Scheme of Nt-acetylation. A Nat acetylates the N-terminal α-amino group of a protein 
by transferring an acetyl moiety (Ac) from Ac-CoA (Starheim et al., 2012). 
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Nt-acetylation is carried out by protein complexes (NatA, NatB, NatC, NatD and 
NatE) that perform most Nt-acetylations in eukaryotes. Each complex consists of a 
catalytic and a varying number of auxiliary subunits, and their function appears to be 
highly conserved across species (Figure 19) (Helbig et al., 2010). Human NatA, NatB 
and NatC were reported to function in translation initiation and in other events in the 
cell, while NatD is a specific nt-acetyltransferase of histone H4 and H2A (Yasuda et al., 
2013). Higher eukaryotic organisms express another type of Nat, NatF. Human NatF 
shows very distinct substrate specificity and contributes to about 10% of the total 
protein Nt-acetylation in the cell (Van Damme et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. The eukaryotic NATS and substrate specificity. The NATs are found on the ribosome 
in both humans and yeast. In humans, Naa10p also acetylates - and -actin post-translationally. NatF is 
only present in higher eukaryotes (Kalvik & Arnesen, 2013). 
 
 
Nt-acetylation is considered an irreversible process that mainly occurs on the 
ribosome during protein synthesis (Foyn et al., 2013).Nt-acetylation appears to be 
essential for life in higher eukaryotes: a mutation in the human Nt-acetyltransferase A, 
more specifically in the Naa10 gene, was shown to be the cause of Ogden syndrome, 
resulting in males that are underdeveloped and die at infancy.  
 
Several distinct NATs have been identified in yeast: NatA, NatB, NatC, NatD 
and NatE which are composed of catalytic and auxiliary subunits. NatD only consist of 
a catalytic subunit, Nat4p. The deletion of NatA leads to defects in sporulation, slow 
growth and failure to enter the G0 phase. NatB-deleted strains exhibit decreased 
utilization of non-fermentable carbon sources, inability to form functional actin 
filaments, defects in mitochondrial and vacuolar inheritance, increased sensitivity to 
Introduction-Chapter2 
45 
 
anti-mitotic drugs and susceptibility to a number of DNA damaging agents (Kamita et 
al., 2011).  
 
 
2.1.1. Nt-acetyltransferase B 
In eukaryotes and yeast, multiple protein complexes are capable of performing 
N-terminal acetylation; one of the most well characterized NATs is the NatB complex. 
NatB subunits are associated with ribosomes in both humans and yeast, and transfer 
an acetyl group to the N-terminus of target proteins. However, a large portion of the 
NatB subunits in humans are present in a non-ribosomal form (Starheim et al., 2012). 
Yeast and human NatB are composed of the catalytic subunit Naa20p (Nat3p) and the 
auxiliary subunit Naa25p (Mdm20p), and acetylate the N-terminal methionine residue 
of substrates with the N-terminal sequence Met-Glu-, Met-Asp- and Met-Asn (Polevoda 
et al., 2003). 
In both humans and yeast, the Naa20 catalytic subunit of NatB localizes to both 
the cytoplasm and the nucleus, while the Naa25 auxiliary subunit is only present in the 
cytoplasm. Both subunits of yNatB are found either in the ribosome-bound or non-
ribosome-bound form, indicating that these proteins can interact with ribosomes but 
also may have other functions (Starheim et al., 2008). In yeast, NatB is one of the 
major NATs and it is responsible for about 15% of all protein Nt-acetylation (Van 
Damme et al., 2012). Several substrates have been reported for yNatB, including 
tropomyosin-1 (Tpm1), the 20S proteosomal subunit and the stress-induced 
carboxypeptidase inhibitor Tfs1p (Van Damme et al., 2012). The naa20Δ and naa25Δ 
mutants display several phenotypes that can be linked to the loss of acetylation of the 
yNatB substrates actin and tropomyosin (Starheim et al., 2008), since Nt-acetylation of 
tropomyosin is required for high affinity binding of tropomyosin to actin. Previous 
studies demonstrated that a strain lacking Naa20 has reduced growth rate, reaches 
lower population densities, and exhibits abnormal morphology, including multiple buds 
and increased cell size (Caesar et al., 2006). Helbig et al. also showed that the effect in 
mitochondrial inheritance observed when in the absence of Nat3 could be attributed to 
the loss of the N-acetyl group of Ugo1p, a protein located in the mitochondrial outer 
membrane where it is required for mitochondrial fusion (Helbig et al., 2010). 
Since the yeast and human NatB substrate specificity is largely conserved (Van 
Damme et al., 2012), yeast has been a great advantage as a model organism to study 
Nt-acetylation. 
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2.1.2. Regulation of Apoptosis by Nt- acetylation 
Apoptosis and Nt-acetylation have previously been associated. A point mutation 
in Naa10p, the catalytic subunit of NatA, results in the reduction of acetylation levels by 
NatA and causes the lethal X-linked disorder in infancy (Rope et al., 2011). Arnesen 
and coworkers also showed that depletion of this Nat induces p53-dependent 
apoptosis and p53-independent growth inhibition (Gromyko et al., 2010). Yi and 
coworkers demonstrated that Nt-acetylation promotes apoptosis and proposed that Ac-
CoA might serve as a signaling molecule that couples apoptotic sensitivity to 
metabolism by regulating protein Nα-acetylation (Yi et al., 2011). They showed that 
protein Nt-acetylation levels are sensitive to alterations in metabolism and to Bcl-xL 
expression, since it leads to reduced levels of Ac-CoA  and hypoacetylation of protein 
N-termini through a Bax/Bak-independent mechanism. This study suggests that 
regulation of Ac-CoA and protein Nt-acetylation may provide a Bax/Bak-independent 
mechanism for Bcl-xL to regulate apoptotic sensitivity (Figure 20) (Yi et al., 2011). They 
also suggest that Bcl-xL might block citrate export from the mitochondria by interacting 
with the voltage-dependent anion channel (VDAC) and that Bcl-xL also inhibits cell 
proliferation, which might indirectly affect acetyl-CoA levels by reducing TCA cycle 
activity (Andersen & Kornbluth, 2011).The same study also showed that reduced levels 
of Ac-CoA mediated by Bcl-xL do not affect N--acetylation of histones H3 and H4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20.  Regulation of Apoptosis by Bcl-xL. Bcl-xL lowers the levels of acetyl-CoA (possibly 
due to an indirect effect upstream of acetyl-CoA), resulting in decreased Nt-acetylation of apoptotic 
mediators such as caspase-2, -3, -9 and Bax. In the case of caspase-2, Nt-acetylation is critical for its 
activation (Andersen & Kornbluth, 2011). 
 
 
NATs have not only been associated with apoptosis but also have a role in 
cancer. hNaa10 in particular has been proposed as both an oncoprotein and a tumour 
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suppressor. It is overexpressed in different types of cancers such as colorectal, lung, 
and breast cancer, and studies have proposed various molecular explanations for the 
role of Naa10 as an oncoprotein (Ren et al., 2008). hNaa10 can exert its effects as a 
major NAT, but also through N--acetylation, directly and/or by recruiting interaction 
partners with lysine acetyltransferase activity (Kalvik & Arnesen, 2013). It has also 
been shown that deletion of hNatB subunits inhibits cell growth and proliferation, and 
disturbs cell cycle progression. The differences in phenotypes resulting from deletions 
of subunits of hNatB could indicate that one or both may have individual functions in 
addition to those of the hNaa20/hNaa25 complex (Starheim et al., 2009). Moreover, 
deletion of hNatC subunits leads to reduced cell proliferation and apoptosis. Cells 
without the catalytic subunit hNaa30 have a stronger phenotype than those with 
knockdown of auxiliary subunits hNaa35 and hNaa38 (Figure 21). These phenotypes 
suggest that hNatC is required for normal cell growth and survival and that all three 
subunits are needed for hNatC activity (Starheim et al., 2009). However, more studies 
are needed in order to understand the function and regulation of Nats and which 
mechanisms mediate their oncogenic and tumor suppressor properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21.  hNaa30Δ of the hNatC complex leads to p53-dependent apoptosis and lead to the 
reduced acetylation of hNaa30p substrates. As a direct or indirect effect of this, p53 is stabilized and 
phosphorylated on Serine37, and subsequently, transcription of p53 downstream proapoptotic genes 
NOXA, KILLER and FAS is activated, resulting in apoptosis (Starheim et al., 2009). 
 
Given these data from the literature, a previous study in our laboratory used 
yeast cells in order to verify whether Bax is acetylated by NatB, affecting its function 
and role in apoptosis. In fact, each Nat acetylates a subset of protein N-termini roughly 
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defined by the N-terminal amino acid sequence and Bax contains in its terminal 
sequence a specific substrate of NatB (Figure 22A, B). 
 
    A                                                                                                         B                                                                                                                                                                                                                                     
 
 
 
 
 
 
 
 
 
Figure 22. Substrate specificity of NatB. Baxα isoform protein sequence (A) is a putative 
substrate of NatB (B). 
 
In this previous study, NAT3 was replaced by the KanMX4 gene cassette in the 
W303-1A strain, through homologous recombination and the positive colony was 
transformed with the plasmids pYES3/CT and pYES3/CT Baxα (Bax wt). After 
confirmation of the clones, viability assays were performed in order to verify if 
expression of Bax in nat3Δ cells affects cell survival (Figure 23). The results suggest 
that expression of Baxα in the deleted strain seems to induce cell death. 
 
 
                                                                       
 
 
 
 
 
 
 
Figure 23. Effect of Baxα in nat3Δ yeast cells. Cell viability was measured as a percentage of 
colony forming units (c.f.u.) at different times on YPD medium after induced by galactose at T0.  Vieira S., 
unpublished data. 
 
The isolation of cytosolic and mitochondrial fractions of all strains was also 
performed to ascertain whether the cellular localization of Bax was affected (Figure 24). 
1 
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Figure 24.  Baxα. Bax translocates to mitochondria of wt and nat3Δ cells expressing Baxα. The 
ability of Bax to induce mitochondria membrane permeabilization might be affected in the absence of Nt-
acetylation, since mitochondria from nat3Δ retains the most fraction of Bax (Vieira S., unpublished data). 
 
 
As can be seen in the figure 24, Bax is translocated to mitochondria in both 
strains expressing Baxα being more evident this translocation in the nat3Δ strain. 
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N-terminal acetylation is a common modification, occurring in the great majority 
of eukaryotic proteins. Is has been thought for a long time that Nt-acetylation protects 
proteins from degradation, but the role of Nt-acetylation is still unclear. It is known that 
the regulation of Bax depends on the interaction with different Bcl-2 family proteins and 
post-translational modifications such as phosphorylation events, which control the 
conformational changes required for Bax activity. Yet, less is known about the 
contribution of other Bax post-translational modifications to cell death. In this work, we 
took advantage of the yeast model system to address this issue, studying acetylation of 
Bax by hNatB using the following approaches: 
 
1- Assess if expression of hNatB reverts the slow growth phenotype and 
complements the morphological defects of yeast nat3Δ cells; 
2- Assess if expression of hNatB affects the survival and mitochondrial 
dysfunction (ROS) of wt and nat3Δ cells expressing Baxα; 
3- Verify if expression of hNatB affects Bax localization and cyt c releasing 
activity. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Materials and 
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2.3.1. Yeast strains and growth conditions  
All strains of Saccharomyces cerevisiae used in this study are listed in Table IV. 
The nat3Δ pYES3-Baxα strain was constructed previously by S. Vieira (unpublished). 
Strains were transformed with the indicated plasmids using the lithium acetate 
method as described before. Transformants were selected on Synthetic Complete (SC) 
medium lacking the appropriate aminoacids plus 2% (w/v) of carbon source and 2% 
agar. Yeast strains were maintained on solid YPD or SC medium (lacking the 
appropriate aminoacids), grown at 30 °C for 48h-72h, stored at 4°C, and refreshed 
every 2-3 weeks. Yeast cultures were grown aerobically in SC medium with 2% 
Glucose or Galactose as a carbon source or in SC medium with 0.5% Lactacte pH 5.5 
supplemented with 0.5% ethanol. Strains transformed with plasmids were grown in SC 
medium lacking the appropriate aminoacids. Cells were incubated at 30 °C with orbital 
shaking (200 rpm) and a liquid/air ratio of 1:5. 
 
Table IV. List of S. cerevisiae strains used in this study 
 
Strain Genotype Reference 
W303-1A pYES3-Baxα W303-1A harboring pYES3-
Baxα 
Silva R. 
nat3Δ pYES3-Baxα nat3Δ harboring pYES3-Baxα   Vieira S. 
W303-1A pYES3-Baxα pAB3461 W303-1A harboring pYES3-
Baxα and pAB3461 
This study 
nat3Δ pYES3-Baxα pAB3461 nat3Δ harboring pYES3-Baxα  
and pAB3461 
This study 
W303-1A pYES3-Baxα pAB3473-
NatB 
W303-1A harboring pYES3-
Baxα and pAB3473-NatB 
This study 
nat3Δ pYES3-Baxα pAB3473-NatB nat3Δ harboring pYES3-Baxα 
and pAB3473-NatB 
This study 
 
 
 
 
2.3.2. Plasmids  
All the plasmids used in this work are listed in Table V.  
 
Table V. List of the plasmids used in this work. 
Plasmid Description Reference 
pAB3461 URA3;AmpR Van Damme et al., 2012 
pAB3473-NatB NatB inserted in pAB3473 Van Damme et al., 2012 
 
 
 
2.3.3. Growth curves and viability assay 
Yeast strains W303-1A pYES3-Baxα pAB3461, W303-1A pYES3-Baxα 
pAB3473-NatB, nat3Δ pYES3-Baxα pAB3461 and nat3Δ pYES3-Baxα pAB3473-NatB 
were first grown in SC medium with 2% of glucose lacking the appropriate aminoacids. 
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Cells were then transferred to SC medium with 0.5% of Lactacte pH 5.5 supplemented 
with 0.5% ethanol and grown to an O.D at 640nm of 0.3-0.5 (exponential phase). Then, 
2% of galactose was added to induce Bax expression. The growth of yeast strains was 
assessed at different times. All incubations were performed at 30°C, 200 r.p.m. 
For viability assay, samples were harvested at the indicated times at an O.D. at 
640 nm of 0.1 and cell viability was measured as a percentage of colony forming units 
(c.f.u.) on YPD medium. Statistical analyses were performed using GraphPad Prism 
Software v5.00 (GraphPad Software, California, USA). P-values lower than 0.05 were 
assumed to represent a significant difference by  Anova. 
 
 
2.3.4. Accumulation of ROS (Flow Cytometry) 
Intracellular superoxide anion was detected by flow cytometry using 
dihydroethidium (DHE) as a probe. For DHE staining, cells were harvested by 
centrifugation, resuspended in 500μL PBS and incubated with 5μg/mL DHE for 30 min 
in the dark. Cells with red fluorescence [FL-3 channel (488/620 nm)] were considered 
to accumulate superoxide anion. 
All flow cytometry assays were performed in an Epics® XL™ (Beckman Coulter) 
flow cytometer, equipped with an argon-ion laser emitting a 488-nm beam at 15mW. 
The population of cells with high homogeneity and frequency was gated in a histogram 
of Side Scatter (SS) x Forward Scatter (FS). Twenty thousand cells per sample were 
analyzed. The resulting data were analyzed with WinMDI 2.8 software. 
 
 
2.3.5. Cell morphology and chitin visualization 
Since the nat3Δ strain shows an abnormal morphology, microscopy was used to 
verify the morphology and cell wall chitin of each yeast strain. Chitin assembly was 
assessed by CFW (Calcofluor-white) staining. Cultures were diluted to 1x107 cells/ml 
and 20l of CFW (100 g/ml) added to 1ml of cell suspensions. Samples were 
incubated at room temperature for 5min and 5l of each suspension placed on a glass 
slide for microscopic visualization (Leica Microsystems DM-5000B). 
 
 
 
2.3.6. Mitochondrial and cytosolic fractionation 
Four hundred milliliters of cells were grown under the same conditions used for 
growth curves, and harvested at the end of exponential phase (OD640=1.4-1.6) after 
14h of galactose induction. Cells were resuspended in Suspension Buffer [60% (v/v) 2 
M Sorbitol, 6% (v/v) 1 M Sodium phosphate (pH 7.5) and 2% (v/v) 0.5 M EDTA] and 
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then digested with 10 mg Zymolyase 20T (ImmunO, MP Biomedicals) to obtain 
spheroplasts, washed twice with 1.2 M sorbitol, and suspended in Lysis Buffer [0.5 M 
Sorbitol, 20 mM Tris/HCl (pH 7.5) and 1 mM EDTA]. Spheroplasts were lysed with a 
few strokes in a glass Dounce homogenizer (tight fitting piston) with care to avoid 
mitochondrial lysis. Homogenates were centrifuged at 2500 rpm for 10 min and the 
supernatant then centrifuged at 15000 rpm for 15 min. The supernatant constitutes the 
cytosolic fraction and was centrifuged two more times at 15000 rpm for 15min to 
eliminate contamination with mitochondria. The pellet, containing the mitochondrial 
fraction, was centrifuged two more times and suspended in Lysis Buffer. Both fractions 
were frozen in liquid nitrogen and stored at -80ºC. Estimation of the protein 
concentration of the fractions was determined by the Bradford method using BSA as a 
standard (Bradford, 1976). 
 
 
 
2.3.6.1. SDS gel electrophoresis/Western Blot 
 
Mitochondrial and cytosolic fractions were separated electrophoretically on a 
15% SDS polyacrylamide gel at 20 mA and transferred to a PVDF membrane as 
described above. Membranes were cut into strips and incubated with the primary 
antibodies: mouse monoclonal anti-yeast phosphoglycerate kinase (PGK1) antibody 
(1:5000, Molecular Probes), mouse monoclonal anti-yeast porin (POR1) antibody 
(1:5000, Molecular Probes), rabbit polyclonal anti-yeast cytochrome c (CYC1) antibody 
(1:2500, custom-made by Millegen), rabbit polyclonal anti-human Bax (BAX) antibody 
(1:5000, Sigma). Membranes were incubated with secondary antibodies against mouse 
or rabbit IgG-peroxidase (1:10000; Sigma Aldrich). Pgk1p and Por1p were used as 
controls for cytosolic and mitochondrial fractions, respectively. Immunodetection of 
bands was revealed by chemiluminescence (Immobilon, Millipore). 
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2.4.1. Expression of human NatB reverts the slow growth and morphology 
defects of yeast nat3Δ cells 
Deletion of yNAA20 (nat3) leads to a reduced growth rate in yeast. Moreover, 
Naa20Δ (nat3Δ) cells showed reduced mating, abnormal morphology and cytoskeleton 
function, defects in mitochondrial division and vacuolar segregation. These defects are 
attributed to the absence of Nt-acetylation in two essential cytoskeleton proteins, actin 
and tropomyosin, substrates of yNatB (Van Damme et al., 2012), and the inability of 
cells to form functional actin cables (Starheim et al., 2012) (Caesar et al., 2006). nat3Δ 
yeast cells are also temperature sensitive for growth and fail to transport mitochondria 
into newly formed buds (Hermann et al., 1997). 
In this work, we first determined if hNatB reverts the slow growth of yeast nat3Δ 
(Figure 25) in cells expressing Baxα. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  Effect of Baxα and hNatB co-expression in yeast nat3Δ growth.  Growth curves of 
S. cerevisiae strain W303-1A expressing Baxα and hNatB along induction started by galactose at T0. 
These data result from the mean of three independent experiments. Values significantly different from 
W303 pBaxα pAB3461: ** P<0.01 and *** P<0.001, 2way Anova Test. 
 
 
As shown in Figure 25, hNatB reverts the growth defect of nat3Δ cells, and had 
no effect in the growth of wt strain (W303 pBax). Yeast strains were also incubated with 
CFW and cell wall chitin was observed by fluorescence microscopy (Figure 26 A, B, C 
and D). 
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               A                                    B                            C                              D 
 
Figure 26. Morphology and chitin visualization of the yeast strains nat3Δ Baxα (A) and nat3Δ 
Baxα expressing hNatB (B) as well as strains wt Baxα (C) and wt Baxα expressing hNatB (D) used as a 
control. 
 
 
Similarly to other studies, we observed that nat3Δ cells are abnormally large 
and heterogeneous in size, exhibit defects in chitin localization, and accumulate small 
vesicles (A). However, in the presence of hNatB, nat3Δ yeast cells show  morphology 
similar to that observed in the wt strain (B, C) though their size remains larger than the 
wild type. These data suggest that hNatB (B) can complement the function performed 
by yeast Nat3 that is required for normal function of the actin cytoskeleton, since loss of 
interaction between actin and tropomyosin in nat3Δ causes dramatic changes in cell 
physiology (Caesar & Blomberg, 2004). These results are in agreement with the 
literature, since hNatB was shown to be active in yeast and partially rescue yNatBΔ 
phenotypes (Van Damme et al., 2012). 
 
 
 
 
2.4.2. Expression of hNatB enhances the survival of wt and nat3Δ cells 
expressing Baxα and protects cells from oxidative stress 
To ascertain the role of hNatB in cell survival of yeast nat3Δ cells expressing Baxα, 
cell survival of the aforementioned strains was measured as a percentage of colony 
forming units (c.f.u.) (Figure 27). 
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Figure 27.  Effect of Baxα and hNatB co-expression in yeast. Cell viability was measured as a 
percentage of colony forming units (c.f.u.) at different times on YPD medium after induced by galactose at 
T0. These data result from the mean of four independent experiments. * P<0.05 and *** P<0.001, 2way 
Anova Test.  
 
After shorter periods of expression of human Baxα, but not after 14h of 
expression, yeast cells lacking Nat3p have decreased cell survival compared to the wt 
strain. At the 14h time point, the nat3Δ strain expressing hNatB shows cell survival 
values similar to the wt strain carrying hNatB, indicating that for longer expression 
times hNatB promotes survival in nat3Δ cells as well as in the wt strain. 
 
Expression of Bax leads to mitochondrial dysfunction in yeast cells (Khoury & 
Greenwood, 2008). In order to verify if Nat3p plays a role in this phenotype, DHE 
staining was used to detected intracellular superoxide anion accumulation in all strains. 
In this experiment the role of hNatB and Baxα in oxidative stress was also observed in 
yeast nat3Δ cells (Figure 28 A, B, C, D and E). 
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Strains W303 pBax 
pAB3461 
W303 pBax 
pNatB 
nat3Δ pBax nat3Δ pBax 
pNatB 
Time 0 14 0 14 0 14 0 14 
Mean fluorescence 
intensity (MnX) 
0,444 4,98 0,582 2,22 0,651 5,68 0,546 2,84 
 
 
Figure 28. ROS accumulations in wt (A) and nat3Δ (C) cells expressing Baxα or co-
expressing Baxα and hNatB (B and D, respectively).  Cells were analysed by flow cytometry using DHE 
staining. Samples were collected before, T0 (black histogram), and after 14h of protein induction (red 
histogram). (E)- Mean fluorescence intensity over time for each strain. This result is representative of three 
independent experiments. 
 
The results obtained by flow cytometry show that there is an accumulation of 
ROS in ynat3Δ and wt strains when Baxα is present, which is partially rescued by 
expression of hNatB. This suggests that hNatB protects cells from Bax-induced 
oxidative stress in both strains. 
 
 
W303 pBaxα pAB3461 W303 pBaxα pNatB 
nat3Δ pBaxα nat3Δ pBaxα pNatB 
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2.4.3. Localization of Baxα and cytochrome c releasing activity in nat3Δ cells 
expressing hNatB 
Bax activation involves subcellular translocation and dimerization. In normal cells, 
Bax is monomeric and found either in the cytosol or loosely linked to membranes. After 
a death stimulus, Bax translocates to the mitochondria where it becomes an integral 
membrane protein (Gross et al., 1999). It is already established that post-translational 
modifications are important for Bax function. For instance, phosphorylation can affect 
the function of Bcl-2 or Bax by altering the ability of these proteins to form 
heterodimers, affecting cell cycle events, regulating cell proliferation and programmed 
cell death (Delivoria-Papadopoulos & Mishra, 2010). In yeast, expression of Bax 
releases cytochrome c to the cytosol and this is prevented by co-expression of anti-
apoptotic proteins. It was described that expression of Bcl-2 alone is able to protect 
yeast cells against death suggesting that at a part of the death pathway may be shared 
between yeast and higher eukaryotes (Priault et al., 1999b). 
One hypothesis of this study was to verify if Bax is acetylated by NatB and 
activated. To test this, the cytosolic and mitochondrial fractions of Baxα-expressing 
cells were isolated and the localization of Baxα and the release of cyt c assessed 
(Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Effect of Nt-acetylation by hNatB on Baxα activity. Bax is translocated to mitochondria 
of wt and nat3Δ cells. The ability of Bax to induce mitochondria membrane permeabilization might be 
affected in the absence of Nt-acetylation, since mitochondria from nat3Δ cells retain most of their cyt c. 
 
 
The localization of Baxα seems to be identical in wt and Δnat3 cells, and located 
preferentially in the cytosol; however, small portions are found in mitochondria. These 
results are in contrast with those obtained previously in the lab, with growth conditions 
in SC medium with 2% lactate and with the difference of not having the empty vector of 
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hNatB, but may reflect that Bax is translocated to mitochondria with different kinetics in 
wt and Δnat3 cells, but the end-point is similar. In agreement, the nat3Δ strain did not 
show increased release of cyt c. This result suggests that Nat3 may affect the kinetics 
of Bax addressing to the mitochondria, but that it does not affect Bax-induced cyt c 
release. It was also apparent that wt and nat3Δ strains carrying hNatB had slightly 
higher release of cyt c. While this was associated with a higher decrease of cyt c 
mitochondrial content for nat3Δ the same was not observed for the wild type. Whether 
it is a specific effect or there was slight contamination of the cytosolic fraction with 
mitochondrial contents remains to be determined. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5. Discussion and Future 
Perspectives 
Discussion and Future Perspectives 
64 
 
The majority of cytosolic proteins in eukaryotes contain a covalently linked 
acetyl moiety at their N terminus. Nt-acetylation has recently been extensively studied, 
since it affects the stability and function of several proteins. This modification occurs on 
the α-amino group of a protein during its synthesis by a conserved family of N-terminal 
acetyltransferases, whose specificity is determined by the amino acid at the mature N 
terminus of the substrate (Holmes et al., 2014). This study aimed to verify if Baxα is 
acetylated by hNatB in normal yeast cells and nat3Δ cells but also if hNatB 
complements the absense of Nat3p. 
At first, an in vivo assay based on growth of yeast cells expressing Baxα and 
hNatB in nat3Δ and wt strain was performed to assess if hNatB complements the slow 
growth of ynat3Δ cells. The results of this assay showed that hNatB partially 
complements the growth of ynat3Δ cells and no differences were found in the wt strain, 
suggesting that hNatB does not affect growth in this strain (Figure 25). The Nat3p 
deletion phenotype in yeast is very clear showing abnormal cell morphology. Another 
aim of this study was to determine whether hNatB was able to reverse this phenotype. 
Our results show that the nat3Δ strain has an abnormal morphology that is reversed by 
the presence of hNatB, thus resembling the cells of the wt strain (Figure 26). This 
suggests that hNatB can complement the functions performed by yeast Nat3 that is 
required for acetylation of actin and tropomyosin that contributes to normal function of 
actin cytoskeleton. 
 
In order to complete these results, cell survival assays were performed to 
understand the role of hNatB in cell survival in yeast cells expressing Baxα and in 
nat3Δ cells. The results obtained through c.f.u. counts reveal that expression of Baxα in 
nat3Δ cells seems to induce cell death that is reversed by expression of hNatB. 
Expression of hNatB in yeast cells partially restores the survival of wt and Δnat3 cells 
expressing Baxα for longer expression times (Figure 27). These results suggest that 
absence of Baxα Nt-acetylation affects yeast survival. 
 
 
Since previous studies have shown that Bax induces mitochondrial 
hyperpolarization and production of ROS (Priault et al., 2003) and deletion of Nat3p 
also associated with a decrease in the function of the actin resulting in a defective 
active cables formation (Polevoda et al., 2003), likely linked to an increased in 
production of ROS, we assessed if hNatB had a role in the oxidative stress caused by 
expressing Baxα and Nat3p deletion in yeast cells. 
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The flow cytometry results obtained by DHE staining indicated that there is an 
accumulation of ROS in nat3Δ and wt strains when Baxα is present which is partially 
rescued by hNatB, suggesting that hNatB had a protective role in oxidative stress in wt 
and nat3Δ strains (Figure 28). This result is in agreement with previous results 
obtained in our lab by Vieira S., which showed an evident increased in ROS production 
in nat3Δ strain (unpublished data). In the future, it would be interesting to optimize the 
Mitotracker Red and Mitotracker Green staining to determine if there are also changes 
in mitochondrial membrane potential, as well as assess if there are alterations in 
mitochondrial fragmentation/degradation. 
 
To ascertain whether acetylation of Baxα by hNatB affect Bax localization and 
activity, cytosolic and mitochondrial fractions from wild type and nat3Δ cells were made 
analyzed by western blot. Baxα is located preferentially in the cytosol however, small 
portions are found in mitochondria of wt and nat3Δ cells, but the location was identical 
in all strains. These results together with those obtained by Vieira S. suggest that 
though Nt-acetylation does not affect the ability of Bax to insert in the outer 
mitochondrial membrane, it may alter the kinetics of Bax mitochondrial 
addressing/insertion. Moreover, it also appears that in the absence of hNatB and yeast 
Nat3p, expression of Bax does not trigger release of cyt c,(Figure 29) Indeed, 
mitochondria from Δnat3 cells retain most of its cyt c which suggests that the ability of 
Bax to induce mitochondria membrane permeabilization might be unaffected in the 
absence of Nt-acetylation. On the other hand, expression of hNatB appears to induce 
cyt c release both in the wt as in the nat3Δ strain. However, it is necessary to 
determine whether this is a specific effect or there was a slight contamination of the 
cytosolic fraction with mitochondrial contents. To discard this possibility would require 
monitoring the integrity of the inner mitochondrial membrane with the citrate synthase 
assay. Washing cytosolic and mitochondrial fractions to eliminate contaminations and 
repeating the extraction would be necessary to draw definitive conclusions. Expression 
of hNatB should also be checked with an anti-HA antibody. Finally, it will also be 
necessary to confirm if Baxα is indeed Nt-terminally acetylated in nat3Δ cells 
expressing hNatB by mass spectroscopy. 
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